Biomedical subjects

C Pilet

Publications and source records attributed to C Pilet.

At least 55 records · Page 3Linked to original sources

PubMed1976

[Influence of the mouse genotype on the sensitivity to Brucella abortus 544].

The susceptibility to brucella infection (Brucella abortus 544) of different inbred mice and outbred CD1 strains has been studied. The degree of infection was determined on days 7 and 11 after challenge. The CBA and DBA2 strains showed greater susceptibility and homogeneity compared to the other strains (C57B16, C3H, C57B16 x DBA2) and to the CD1 mice. The kinetics of infection in DBA2 and CBA, compared to those of the CD1 for a longer period, show that the degree of infection decreases rapidly after 11 days. However, 90 days after challenge, the level of infection in DBA2 mice remains higher than in CBA and CD1. The DBA2 strain seems able to provide an improvement for anti-brucella vaccine control.

Animals↗

PubMed1976

[Evaluation of antibrucellosis vaccines using guinea pigs].

In the preliminary stage of a global study made in our laboratory to compare the control technics of antibrucella vaccines (abortus) both in mice and guinea pigs, we have studied the kinetics of brucella infection in the Hartley guinea pig after various doses of Brucella abortus strain 544. Two trials have been carried out: the first with 5000 and 10000 bacteria and the second with 5000, 10000 and 30000 bacteria. The results obtained allow to envisage the use of a challenge dose of at least 10000 bacteria (instead of 5000) and the sacrifice of animals at the 4th week (a gain of two weeks compared to the present protocol).

Animals↗

PubMed1976

[Brucella and modification of the host response to bacterial and viral infection. Effect of the S-R variation].

Within the framework of a study on the immunostimulant properties of Brucella abortus and of its extracts, we have investigated the protective activity on infection of mice by Klebsiella pneumoniae and on Charlotte Friend's leukemia, of inactivated Brucella abortus and brucella lysates by ultrasound. The injection of inactivated B 19 R preparations and their lysates three days before infection by klebsiella has allowed to protect mice against a large number of DL50 (100 and 1000 in certain cases). To determine the role of the surface antigen in this type of immunostimulant, the activity of the B 19 R inactivated preparations has also been examined. It appears that the protection obtained by the injection on day J + 3, in relation to the infection, does not depend on the presence of the complete surface antigen, while the long term effect seems to be more dependent on this. The development of Charlotte Friend's leukemia has been favourably influenced by the previous injection of B 19 S or inactivated B 19 R. Immunotherapy on days J + 1 or J + 3 gave encouraging results with B 19 R, but facilitation with B 19 S. These results confirm the immunostimulant activity of brucella which has already been reported by ourselves and by other authors.

Animals↗

PubMed1975

[Pharmacopoeia and veterinary medicine].

The A recalls briefly the evolution of the veterinary pharmacopoeias. They were at first national and became later international. The A. describes the situation of the veterinary drugs and of their inclusion in the national pharmacopoeias, as far as the European countries are concerned. Are we supposed to assign to them, because of their specificity, a special section in the pharmacopoeia or should we set up a special pharmacopoeia for them? In view of the effects they have on public health should we incorporate them into the pharmacopoeia in the same forms as the human drugs? The A. relates the arguments in favor of each of these points of view. Whichever the decision will be taken to solve this problem, the A. emphasizes the usefulness of the insertion of veterinary drugs in a pharmacopoeia, because of the improper use that some countries make of this type of drugs and because of the consequences this use can possibily have on public health.

Aged↗

PubMed1974